clinical trial · NCT06128564
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
Hoffmann-La Roche·phase2·active not recruiting·n = 13
Duchenne Muscular Dystrophydelandistrogene moxeparvovec
brief summary
This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
started
Nov 29, 2023
primary completion
Feb 28, 2030
completion
Jan 30, 2034
last updated
Feb 10, 2026
official title
A Two-Part, Open-Label Systemic Gene Delivery Study to Evaluate the Safety and Expression of RO7494222 (SRP-9001) in Subjects Under the Age of Four With Duchenne Muscular Dystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol